Compare KRMD & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | EARN |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.7M | 200.3M |
| IPO Year | 2019 | 2012 |
| Metric | KRMD | EARN |
|---|---|---|
| Price | $4.30 | $4.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $6.50 | $5.38 |
| AVG Volume (30 Days) | 131.9K | ★ 409.0K |
| Earning Date | 05-06-2026 | 03-04-2026 |
| Dividend Yield | N/A | ★ 21.01% |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $20.32 | $7.69 |
| Revenue Next Year | $17.38 | $19.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $1.87 | $4.27 |
| 52 Week High | $6.61 | $6.08 |
| Indicator | KRMD | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 47.22 |
| Support Level | $4.08 | $4.43 |
| Resistance Level | $4.34 | $5.36 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 43.24 | 82.43 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.